Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at UC Irvine UCLA UCSD
Dates
study started
completion around

Description

Summary

This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.

Official Title

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Details

Keywords

Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Melanoma, Cutaneous Malignant Melanoma, Skin Neoplasms, Interferons, Interferon-alpha, Interferon alpha-2, Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT01274338
Phase
Phase 3 Skin Cancer/Melanoma Research Study
Study Type
Interventional
Participants
About 1673 people participating
Last Updated